197 related articles for article (PubMed ID: 12834696)
1. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas.
Girmens JF; Erginay A; Massin P; Scigalla P; Gaudric A; Richard S
Am J Ophthalmol; 2003 Jul; 136(1):194-6. PubMed ID: 12834696
[TBL] [Abstract][Full Text] [Related]
2. Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416.
Aiello LP; George DJ; Cahill MT; Wong JS; Cavallerano J; Hannah AL; Kaelin WG
Ophthalmology; 2002 Sep; 109(9):1745-51. PubMed ID: 12208726
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel-Lindau disease.
Wong WT; Liang KJ; Hammel K; Coleman HR; Chew EY
Ophthalmology; 2008 Nov; 115(11):1957-64. PubMed ID: 18789534
[TBL] [Abstract][Full Text] [Related]
4. Effect of intravitreal dexamethasone on macular edema in von Hippel-Lindau disease assessed using swept-source optical coherence tomography: a case report.
Minnella AM; Pagliei V; Maceroni M; Federici M; Gambini G; Caporossi A
J Med Case Rep; 2018 Sep; 12(1):248. PubMed ID: 30185211
[TBL] [Abstract][Full Text] [Related]
5. Verteporfin photodynamic therapy for retinal hemangioblastoma associated with Von Hippel-Lindau disease in a 9-year-old child.
Lazzeri S; Figus M; Di Bartolo E; Rizzo S; Nardi M
Clin Exp Ophthalmol; 2011 Mar; 39(2):179-81. PubMed ID: 21040313
[No Abstract] [Full Text] [Related]
6. Antiangiogenic therapy for von Hippel-Lindau disease.
Madhusudan S; Deplanque G; Braybrooke JP; Cattell E; Taylor M; Price P; Tsaloumas MD; Moore N; Huson SM; Adams C; Frith P; Scigalla P; Harris AL
JAMA; 2004 Feb; 291(8):943-4. PubMed ID: 14982909
[No Abstract] [Full Text] [Related]
7. Case 2. Hemangioblastomas: diagnosis of von Hippel-Lindau disease and antiangiogenic treatment with SU5416.
Schuch G; de Wit M; Höltje J; Laack E; Schilling G; Hossfeld DK; Fiedler W; Scigalla P; Jacobs MS
J Clin Oncol; 2005 May; 23(15):3624-6. PubMed ID: 15908674
[No Abstract] [Full Text] [Related]
8. [Intravitreal anti-VEGF therapy for capillary hemangioblastomas in von Hippel-Lindau disease].
Michels S; Messmer E; Sutter F; Kurz-Levin MM
Klin Monbl Augenheilkd; 2008 Apr; 225(4):292-4. PubMed ID: 18401796
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina.
Dahr SS; Cusick M; Rodriguez-Coleman H; Srivastava SK; Thompson DJ; Linehan WM; Ferris FL; Chew EY
Retina; 2007 Feb; 27(2):150-8. PubMed ID: 17290195
[TBL] [Abstract][Full Text] [Related]
10. Combined therapy guided by multimodal imaging of fifteen retinal capillary hemangioblastomas in a monocular Von Hippel- Lindau syndrome case report.
Guo J; Du L; Zhou P; Guo X; Dai F; Jin X
BMC Ophthalmol; 2022 May; 22(1):205. PubMed ID: 35524216
[TBL] [Abstract][Full Text] [Related]
11. Successful Treatment Response of a Juxtapapillary Retinal Capillary Hemangioblastoma Due to von Hippel-Lindau Syndrome with Belzutifan in a Pediatric Patient.
Mustafi D; Huang J; Ting MA; Waligorski N; Stacey AW; Huang LC
Retina; 2024 May; 44(5):e31-e33. PubMed ID: 38100768
[No Abstract] [Full Text] [Related]
12. Photodynamic Therapy for Retinal Hemangioblastoma: Treatment Outcomes of 17 Consecutive Patients.
Di Nicola M; Williams BK; Hua J; Bekerman VP; Mashayekhi A; Shields JA; Shields CL
Ophthalmol Retina; 2022 Jan; 6(1):80-88. PubMed ID: 33892136
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Retinal Changes Following Intravitreal Aflibercept in 2 Patients With Von Hippel-Lindau Disease-Related Retinal Capillary Hemangioblastoma.
Konstantinou EK; Kodati S; Wiley HE; Keenan TDL; Cukras CA; Johnston RH; Thavikulwat AT
JAMA Ophthalmol; 2022 Dec; 140(12):1243-1244. PubMed ID: 36301552
[TBL] [Abstract][Full Text] [Related]
14. Continuous angiogenesis inhibition in the treatment for von Hippel-Lindau-related hemangioblastomas of retina and spinal cord.
Salim DK
J Oncol Pharm Pract; 2019 Dec; 25(8):2049-2051. PubMed ID: 31694494
[TBL] [Abstract][Full Text] [Related]
15. CLINICALLY INVISIBLE RETINAL HEMANGIOBLASTOMAS DETECTED BY SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY AND FLUORESCEIN ANGIOGRAPHY IN TWINS.
Schoen MA; Shields CL; Say EAT; Douglass AM; Shields JA; Jampol LM
Retin Cases Brief Rep; 2018 Winter; 12(1):12-16. PubMed ID: 27533642
[TBL] [Abstract][Full Text] [Related]
16. von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy.
Harris AL
Oncologist; 2000; 5 Suppl 1():32-6. PubMed ID: 10804089
[TBL] [Abstract][Full Text] [Related]
17. TWO CASES OF VON HIPPEL-LINDAU SYNDROME-ASSOCIATED RETINAL HEMANGIOBLASTOMA TREATED WITH BELZUTIFAN.
Grimes JM; Gershkovich A; Bogomolny D; Marr BP
Retin Cases Brief Rep; 2024 May; 18(3):319-322. PubMed ID: 36730578
[TBL] [Abstract][Full Text] [Related]
18. Value of Optical Coherence Tomography Angiography Imaging in Diagnosis and Treatment of Hemangioblastomas in von Hippel-Lindau Disease.
Lang SJ; Cakir B; Evers C; Ludwig F; Lange CA; Agostini HT
Ophthalmic Surg Lasers Imaging Retina; 2016 Oct; 47(10):935-946. PubMed ID: 27759860
[TBL] [Abstract][Full Text] [Related]
19. MANAGEMENT OF RETINAL HEMANGIOBLASTOMA IN VON HIPPEL-LINDAU DISEASE.
Wiley HE; Krivosic V; Gaudric A; Gorin MB; Shields C; Shields J; Aronow ME; Chew EY
Retina; 2019 Dec; 39(12):2254-2263. PubMed ID: 31259811
[TBL] [Abstract][Full Text] [Related]
20. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
Jimenez C; Cabanillas ME; Santarpia L; Jonasch E; Kyle KL; Lano EA; Matin SF; Nunez RF; Perrier ND; Phan A; Rich TA; Shah B; Williams MD; Waguespack SG
J Clin Endocrinol Metab; 2009 Feb; 94(2):386-91. PubMed ID: 19017755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
